Efficacy and Safety of Lamivudine or Telbivudine in Preventing Mother-to-Child Transmission of Hepatitis B Virus: A Real-World Study
المؤلفون المشاركون
Yi, Wei
Li, Zhenhua
Duan, Xuefei
Hu, Yuhong
Zhou, Mingfang
Liu, Min
Kang, Kai
Cai, Haodong
Fu, Dong
Gao, Xuesong
المصدر
العدد
المجلد 2020، العدد 2020 (31 ديسمبر/كانون الأول 2020)، ص ص. 1-6، 6ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2020-04-27
دولة النشر
مصر
عدد الصفحات
6
التخصصات الرئيسية
الملخص EN
Background.
There are few large sample studies evaluating the safety and efficacy of lamivudine (LAM) or telbivudine (LdT) in preventing hepatitis B mother-to-child transmission (MTCT) in highly viremic mothers in the third trimester of pregnancy in real-world settings.
The purpose of this study was to analyze a large sample size of HBV-infected mothers to better understand the safety and efficacy of LAM and LdT under the aforementioned criteria.
Methods.
During the period of November 2008 to November 2017, we retrospectively enrolled mothers with HBV DNA>1×106 IU/mL who received LAM or LdT during the third trimester of pregnancy and compared them to untreated mothers.
All mothers were divided into the three following groups: the LAM group, the LdT group, and the control group.
Results.
A total of 2624 HBV-infected mothers were enrolled in the study, with 363 in the LAM group, 1283 in the LdT group, and 978 in the control group.
The MTCT rates were significantly lower in the LAM or LdT group than that in the control group (0.4% or 0.3% versus 9.0%, P<0.001).
Infants born to untreated mothers had a significantly higher risk of HBV infection (OR=28.6, 95% CI: 10.4–78.7, P<0.001).
There were no significant differences in perinatal complications between the three groups (P>0.05).
There were also no differences for gestational age or infants’ height, weight, Apgar scores, or birth defect rates.
Postpartum discontinuation of antiviral therapy did not seem to increase the risk of postpartum alanine aminotransferase (ALT) flare.
Conclusion.
LAM or LdT treatment initiated in the third trimester for mothers with HBV DNA>1×106 IU/mL was equally safe and effective in preventing MTCT.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Li, Zhenhua& Duan, Xuefei& Hu, Yuhong& Zhou, Mingfang& Liu, Min& Kang, Kai…[et al.]. 2020. Efficacy and Safety of Lamivudine or Telbivudine in Preventing Mother-to-Child Transmission of Hepatitis B Virus: A Real-World Study. BioMed Research International،Vol. 2020, no. 2020, pp.1-6.
https://search.emarefa.net/detail/BIM-1131614
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Li, Zhenhua…[et al.]. Efficacy and Safety of Lamivudine or Telbivudine in Preventing Mother-to-Child Transmission of Hepatitis B Virus: A Real-World Study. BioMed Research International No. 2020 (2020), pp.1-6.
https://search.emarefa.net/detail/BIM-1131614
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Li, Zhenhua& Duan, Xuefei& Hu, Yuhong& Zhou, Mingfang& Liu, Min& Kang, Kai…[et al.]. Efficacy and Safety of Lamivudine or Telbivudine in Preventing Mother-to-Child Transmission of Hepatitis B Virus: A Real-World Study. BioMed Research International. 2020. Vol. 2020, no. 2020, pp.1-6.
https://search.emarefa.net/detail/BIM-1131614
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1131614
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر